Europe Addresses Antibiotic Resistance - Pharmaceutical Technology

Latest Issue

Latest Issue
PharmTech Europe

Europe Addresses Antibiotic Resistance

Pharmaceutical Technology Europe
Volume 22, Issue 12

In summary

Antibiotic resistance remains a very serious threat due to the limitations of current agents and poor public knowledge about bacterial infections. The European Antibiotic Awareness Day campaign represents a continuing effort to combat these problems across the region, but measures are also needed to boost new pharmaceutical industry R&D efforts. Although the 2009 European Observatory on Health Systems and Policies report was a welcome step forward in summarising thinking of how to stimulate new industry research, it has not yet prompted governments to implement specific incentives. In 2009, a survey among European intensive care physicians found that 53% had treated at least one patient infected with a bacterium totally or almost totally resistant to available antibiotics during the previous 6 months.10 Worrying developments such as these are a warning that governments must bring a sense of urgency to incentivising new antibiotic R&D efforts.


1. About European Antibiotic Awareness Day (2008).

2. The overuse of antibiotics — Eurobarometer statistics.

3. E. Mossialos, et al., Policies and incentives for promoting innovation in antibiotic research (2010).

4. Antimicrobial Resistance, Eurobarometer 72.5 (2009).

5. Les Antibiotiques, Eurobarometer Special (2003).

6. C.A.M. McNulty, J. Antimicrob. Chemo., 65,1526-1533 (2010).

7. S. Coenen, et al., Acta Clinica Belgica, 63-5 (2008).

8. B. Huttner. Antibiotics Are Not Automatic Anymore — The French National Campaign To Cut Antibiotic Overuse. PLoS Medicine 6(6) (2009).

9. L. Jarvis, An Uphill Battle (2008).

10. A. Lepape, Eurosurveillance, 14(45), 12 (2009).


blog comments powered by Disqus
LCGC E-mail Newsletters

Subscribe: Click to learn more about the newsletter
| Weekly
| Monthly
| Weekly

Which of the following business challenge poses the greatest threat to your company?
Building a sustainable pipeline of products
Attracting a skilled workforce
Obtaining/maintaining adequate financing
Regulatory compliance
Building a sustainable pipeline of products
Attracting a skilled workforce
Obtaining/maintaining adequate financing
Regulatory compliance
View Results
Eric Langer Outsourcing Outlook Eric LangerBiopharma Outsourcing Activities Update
Cynthia Challener, PhD Ingredients Insider Cynthia Challener, PhDAppropriate Process Design Critical for Commercial Manufacture of Highly Potent APIs
Jill Wechsler Regulatory Watch Jill Wechsler FDA and Manufacturers Seek a More Secure Drug Supply Chain
Sean Milmo European Regulatory WatchSean MilmoQuality by Design?Bridging the Gap between Concept and Implementation
Report: Pfizer Makes $101 Billion Offer to AstraZeneca
Medicare Payment Data Raises Questions About Drug Costs
FDA Wants You!
A New Strategy to Tackle Antibiotic Resistance
Drug-Diagnostic Development Stymied by Payer Concerns
Source: Pharmaceutical Technology Europe,
Click here